Alemtuzumab, a humanized anti-CD52 antibody, has shown promise in tolerogenic induction protocols, requiring minimal maintenance immunosuppression.

• 阿仑单抗；一种人源性抗-CD52抗体；在免疫耐受诱导方案中效果显著；需要最少的免疫抑制维持药物.